{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T10:52:25Z","timestamp":1761562345274,"version":"3.37.3"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2018,2,26]],"date-time":"2018-02-26T00:00:00Z","timestamp":1519603200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100005788","name":"Medical University of Vienna","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100005788","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2018,6]]},"DOI":"10.1007\/s00259-018-3937-z","type":"journal-article","created":{"date-parts":[[2018,2,26]],"date-time":"2018-02-26T01:18:33Z","timestamp":1519607913000},"page":"931-940","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Ultra-early response assessment in lymphoma treatment: [18F]FDG PET\/MR captures changes in glucose metabolism and cell density within the first 72\u00a0hours of treatment"],"prefix":"10.1007","volume":"45","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8786-8686","authenticated-orcid":false,"given":"Marius E.","family":"Mayerhoefer","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Markus","family":"Raderer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ulrich","family":"Jaeger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philipp","family":"Staber","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barbara","family":"Kiesewetter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniela","family":"Senn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ferdia A.","family":"Gallagher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kevin","family":"Brindle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edit","family":"Porpaczy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Weber","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dominik","family":"Berzaczy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ingrid","family":"Simonitsch-Klupp","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian","family":"Sillaber","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cathrin","family":"Skrabs","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander","family":"Haug","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,2,26]]},"reference":[{"issue":"27","key":"3937_CR1","doi-asserted-by":"publisher","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","volume":"32","author":"BD Cheson","year":"2014","unstructured":"Cheson BD, Fisher RI, Barrington SF, Cavalli F, Schwartz LH, Zucca E, et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol. 2014;32(27):3059\u201368.","journal-title":"J Clin Oncol"},{"issue":"3","key":"3937_CR2","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1093\/annonc\/mds517","volume":"24","author":"M Ghielmini","year":"2013","unstructured":"Ghielmini M, Vitolo U, Kimby E, Montoto S, Walewski J, Pfreundschuh M, et al. ESMO guidelines consensus conference on malignant lymphoma 2011 part 1: diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL) and chronic lymphocytic leukemia (CLL). Ann Oncol. 2013;24(3):561\u201376.","journal-title":"Ann Oncol"},{"issue":"5","key":"3937_CR3","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.1007\/s00259-013-2686-2","volume":"41","author":"L Kostakoglu","year":"2014","unstructured":"Kostakoglu L, Cheson BD. Current role of FDG PET\/CT in lymphoma. Eur J Nucl Med Mol Imaging. 2014;41(5):1004\u201327.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"8","key":"3937_CR4","doi-asserted-by":"publisher","first-page":"2108","DOI":"10.1093\/annonc\/mdt137","volume":"24","author":"S Luminari","year":"2013","unstructured":"Luminari S, Biasoli I, Arcaini L, Versari A, Rusconi C, Merli F, et al. The use of FDG-PET in the initial staging of 142 patients with follicular lymphoma: a retrospective study from the FOLL05 randomized trial of the Fondazione Italiana Linfomi. Ann Oncol. 2013;24(8):2108\u201312.","journal-title":"Ann Oncol"},{"issue":"1","key":"3937_CR5","doi-asserted-by":"publisher","first-page":"W91","DOI":"10.2214\/AJR.09.2637","volume":"194","author":"CG Cronin","year":"2010","unstructured":"Cronin CG, Swords R, Truong MT, Viswanathan C, Rohren E, Giles FJ, et al. Clinical utility of PET\/CT in lymphoma. AJR Am J Roentgenol. 2010;194(1):W91\u2013103.","journal-title":"AJR Am J Roentgenol"},{"issue":"2","key":"3937_CR6","doi-asserted-by":"publisher","first-page":"279","DOI":"10.3109\/10428190903440953","volume":"51","author":"R Watanabe","year":"2010","unstructured":"Watanabe R, Tomita N, Takeuchi K, Sakata S, Tateishi U, Tanaka M, et al. SUVmax in FDG-PET at the biopsy site correlates with the proliferation potential of tumor cells in non-Hodgkin lymphoma. Leuk Lymphoma. 2010;51(2):279\u201383.","journal-title":"Leuk Lymphoma"},{"issue":"6","key":"3937_CR7","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1002\/1522-2594(200006)43:6<828::AID-MRM8>3.0.CO;2-P","volume":"43","author":"H Lyng","year":"2000","unstructured":"Lyng H, Haraldseth O, Rofstad EK. Measurement of cell density and necrotic fraction in human melanoma xenografts by diffusion weighted magnetic resonance imaging. Magn Reson Med. 2000;43(6):828\u201336.","journal-title":"Magn Reson Med"},{"key":"3937_CR8","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1102\/1470-7330.2012.9048","volume":"12","author":"C Lin","year":"2012","unstructured":"Lin C, Luciani A, Itti E, Haioun C, Safar V, Meignan M, et al. Whole-body diffusion magnetic resonance imaging in the assessment of lymphoma. Cancer Imaging. 2012;12:403\u20138.","journal-title":"Cancer Imaging"},{"issue":"6","key":"3937_CR9","doi-asserted-by":"publisher","first-page":"1522","DOI":"10.1002\/jmri.25300","volume":"44","author":"M Sun","year":"2016","unstructured":"Sun M, Cheng J, Zhang Y, Wang F, Meng Y, Fu X. Application value of diffusion weighted whole body imaging with background body signal suppression in monitoring the response to treatment of bone marrow involvement in lymphoma. J Magn Reson Imaging. 2016;44(6):1522\u20139.","journal-title":"J Magn Reson Imaging"},{"issue":"11","key":"3937_CR10","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1097\/RLU.0000000000001395","volume":"41","author":"ME Mayerhoefer","year":"2016","unstructured":"Mayerhoefer ME, Karanikas G, Kletter K, Kiesewetter B, Weber M, Rausch I, et al. Can interim 18F-FDG PET or diffusion-weighted MRI predict end-of-treatment outcome in FDG-avid MALT lymphoma after rituximab-based therapy? A preliminary study in 15 patients. Clin Nucl Med. 2016;41(11):837\u201343.","journal-title":"Clin Nucl Med"},{"issue":"3","key":"3937_CR11","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1148\/rg.2015140145","volume":"35","author":"S Toledano-Massiah","year":"2015","unstructured":"Toledano-Massiah S, Luciani A, Itti E, Zerbib P, Vignaud A, Belhadj K, et al. Whole-body diffusion-weighted imaging in Hodgkin lymphoma and diffuse large B-cell lymphoma. Radiographics. 2015;35(3):747\u201364.","journal-title":"Radiographics"},{"issue":"11","key":"3937_CR12","doi-asserted-by":"publisher","first-page":"2506","DOI":"10.1158\/1078-0432.CCR-14-2454","volume":"21","author":"ME Mayerhoefer","year":"2015","unstructured":"Mayerhoefer ME, Karanikas G, Kletter K, Prosch H, Kiesewetter B, Skrabs C, et al. Evaluation of diffusion-weighted magnetic resonance imaging for follow-up and treatment response assessment of lymphoma: results of an 18F-FDG-PET\/CT-controlled prospective study in 64 patients. Clin Cancer Res. 2015;21(11):2506\u201313.","journal-title":"Clin Cancer Res"},{"issue":"27","key":"3937_CR13","doi-asserted-by":"publisher","first-page":"3048","DOI":"10.1200\/JCO.2013.53.5229","volume":"32","author":"SF Barrington","year":"2014","unstructured":"Barrington SF, Mikhaeel NG, Kostakoglu L, Meignan M, Hutchings M, M\u00fceller SP, et al. Role of imaging in the staging and response assessment of lymphoma: consensus of the International Conference on Malignant Lymphomas Imaging Working Group. J Clin Oncol. 2014;32(27):3048\u201358.","journal-title":"J Clin Oncol"},{"issue":"26","key":"3937_CR14","doi-asserted-by":"publisher","first-page":"4385","DOI":"10.1200\/JCO.2008.19.7814","volume":"27","author":"C Furth","year":"2009","unstructured":"Furth C, Steffen IG, Amthauer H, Ruf J, Misch D, Sch\u00f6nberger S, et al. Early and late therapy response assessment with [18F]fluorodeoxyglucose positron emission tomography in pediatric Hodgkin\u2019s lymphoma: analysis of a prospective multicenter trial. J Clin Oncol. 2009;27(26):4385\u201391.","journal-title":"J Clin Oncol"},{"issue":"9","key":"3937_CR15","doi-asserted-by":"publisher","first-page":"1312","DOI":"10.1007\/s00259-013-2435-6","volume":"40","author":"E Itti","year":"2013","unstructured":"Itti E, Meignan M, Berriolo-Riedinger A, Biggi A, Cashen AF, V\u00e9ra P, et al. An international confirmatory study of the prognostic value of early PET\/CT in diffuse large B-cell lymphoma: comparison between Deauville criteria and \u0394SUVmax. Eur J Nucl Med Mol Imaging. 2013;40(9):1312\u201320.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"3937_CR16","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1182\/blood-2010-12-327767","volume":"118","author":"RO Casasnovas","year":"2011","unstructured":"Casasnovas RO, Meignan M, Berriolo-Riedinger A, Bardet S, Julian A, Thieblemont C, et al. SUVmax reduction improves early prognosis value of interim positron emission tomography scans in diffuse large B-cell lymphoma. Blood. 2011;118:37\u201343.","journal-title":"Blood"},{"key":"3937_CR17","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1016\/S1470-2045(17)30103-1","volume":"18","author":"P Borchmann","year":"2017","unstructured":"Borchmann P, Haverkamp H, Lohri A, Mey U, Kreissl S, Greil R, et al. Progression-free survival of early interim PET-positive patients with advanced stage Hodgkin\u2019s lymphoma treated with BEACOPPescalated alone or in combination with rituximab (HD18): an open-label, international, randomised phase 3 study by the German Hodgkin Study Group. Lancet Oncol. 2017;18:454\u201363.","journal-title":"Lancet Oncol"},{"issue":"Suppl 1","key":"3937_CR18","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1007\/s00259-017-3690-8","volume":"44","author":"SF Barrington","year":"2017","unstructured":"Barrington SF, Kluge R. FDG PET for therapy monitoring in Hodgkin and non-Hodgkin lymphomas. Eur J Nucl Med Mol Imaging. 2017;44(Suppl 1):97\u2013110.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"12","key":"3937_CR19","doi-asserted-by":"publisher","first-page":"2018","DOI":"10.1007\/s00259-017-3758-5","volume":"44","author":"J Lazarovici","year":"2017","unstructured":"Lazarovici J, Terroir M, Arfi-Rouche J, Michot JM, Mussot S, Florea V, et al. Poor predictive value of positive interim FDG-PET\/CT in primary mediastinal large B-cell lymphoma. Eur J Nucl Med Mol Imaging. 2017;44(12):2018\u201324.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"6","key":"3937_CR20","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1080\/10428194.2016.1236380","volume":"58","author":"SH Moon","year":"2017","unstructured":"Moon SH, Lee AY, Kim WS, Kim SJ, Cho YS, Choe YS, et al. Value of interim FDG PET\/CT for predicting outcome of patients with angioimmunoblastic T-cell lymphoma. Leuk Lymphoma. 2017;58(6):1341\u20138.","journal-title":"Leuk Lymphoma"},{"issue":"7","key":"3937_CR21","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1007\/s00259-016-3315-7","volume":"43","author":"NG Mikhaeel","year":"2016","unstructured":"Mikhaeel NG, Smith D, Dunn JT, Phillips M, M\u00f8ller H, Fields PA, et al. Combination of baseline metabolic tumour volume and early response on PET\/CT improves progression-free survival prediction in DLBCL. Eur J Nucl Med Mol Imaging. 2016;43(7):1209\u201319.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"5","key":"3937_CR22","doi-asserted-by":"publisher","first-page":"728","DOI":"10.2967\/jnumed.115.166769","volume":"57","author":"H Sch\u00f6der","year":"2016","unstructured":"Sch\u00f6der H, Zelenetz AD, Hamlin P, Gavane S, Horwitz S, Matasar M, et al. Prospective study of 3\u2032-deoxy-3\u2032-18F-fluorothymidine PET for early interim response assessment in advanced-stage B-cell lymphoma. J Nucl Med. 2016;57(5):728\u201334.","journal-title":"J Nucl Med"},{"issue":"6","key":"3937_CR23","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1593\/neo.09254","volume":"11","author":"TH Witney","year":"2009","unstructured":"Witney TH, Kettunen MI, Day SE, Hu DE, Neves AA, Gallagher FA, et al. A comparison between radiolabeled fluorodeoxyglucose uptake and hyperpolarized (13)C-labeled pyruvate utilization as methods for detecting tumor response to treatment. Neoplasia. 2009;11(6):574\u201382.","journal-title":"Neoplasia"},{"issue":"9","key":"3937_CR24","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.1016\/j.ejrad.2014.05.027","volume":"83","author":"M Horger","year":"2014","unstructured":"Horger M, Claussen C, Kramer U, Fenchel M, Lichy M, Kaufmann S. Very early indicators of response to systemic therapy in lymphoma patients based on alterations in water diffusivity \u2013 a preliminary experience in 20 patients undergoing whole-body diffusion-weighted imaging. Eur J Radiol. 2014;83(9):1655\u201364.","journal-title":"Eur J Radiol"},{"issue":"2","key":"3937_CR25","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1177\/0284185114526087","volume":"56","author":"T Hagtvedt","year":"2015","unstructured":"Hagtvedt T, Seierstad T, Lund KV, L\u00f8ndalen AM, Bogsrud TV, Smith HJ, et al. Diffusion-weighted MRI compared to FDG PET\/CT for assessment of early treatment response in lymphoma. Acta Radiol. 2015;56(2):152\u20138.","journal-title":"Acta Radiol"},{"issue":"6","key":"3937_CR26","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1007\/s00259-014-2705-y","volume":"41","author":"M Meignan","year":"2014","unstructured":"Meignan M, Sasanelli M, Casasnovas RO, Luminari S, Fioroni F, Coriani C, et al. Metabolic tumour volumes measured at staging in lymphoma: methodological evaluation on phantom experiments and patients. Eur J Nucl Med Mol Imaging. 2014;41(6):1113\u201322.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"30","key":"3937_CR27","doi-asserted-by":"publisher","first-page":"3618","DOI":"10.1200\/JCO.2016.66.9440","volume":"34","author":"M Meignan","year":"2016","unstructured":"Meignan M, Cottereau AS, Versari A, Chartier L, Dupuis J, Boussetta S, et al. Baseline metabolic tumor volume predicts outcome in high-tumor-burden follicular lymphoma: a pooled analysis of three multicenter studies. J Clin Oncol. 2016;34(30):3618\u201326.","journal-title":"J Clin Oncol"},{"issue":"15","key":"3937_CR28","doi-asserted-by":"publisher","first-page":"3801","DOI":"10.1158\/1078-0432.CCR-15-2825","volume":"22","author":"AS Cottereau","year":"2016","unstructured":"Cottereau AS, Lanic H, Mareschal S, Meignan M, Vera P, Tilly H, et al. Molecular profile and FDG-PET\/CT total metabolic tumor volume improve risk classification at diagnosis for patients with diffuse large B-cell lymphoma. Clin Cancer Res. 2016;22(15):3801\u20139.","journal-title":"Clin Cancer Res"},{"issue":"16","key":"3937_CR29","doi-asserted-by":"publisher","first-page":"2717","DOI":"10.1200\/JCO.2007.13.1391","volume":"26","author":"WH Wilson","year":"2008","unstructured":"Wilson WH, Dunleavy K, Pittaluga S, Hegde U, Grant N, Steinberg SM, et al. Phase II study of dose-adjusted EPOCH-rituximab in untreated diffuse large B-cell lymphoma with analysis of germinal center and post-germinal center biomarkers. J Clin Oncol. 2008;26(16):2717\u201324.","journal-title":"J Clin Oncol"},{"issue":"4","key":"3937_CR30","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1111\/bjh.13463","volume":"170","author":"C Howlett","year":"2015","unstructured":"Howlett C, Snedecor SJ, Landsburg DJ, Svoboda J, Chong EA, Schuster SJ, et al. Front-line, dose-escalated immunochemotherapy is associated with a significant progression-free survival advantage in patients with double-hit lymphomas: a systematic review and meta-analysis. Br J Haematol. 2015;170(4):504\u201314.","journal-title":"Br J Haematol"},{"issue":"9","key":"3937_CR31","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.1038\/bjc.2015.134","volume":"112","author":"E Papaevangelou","year":"2015","unstructured":"Papaevangelou E, Almeida GS, Jamin Y, Robinson SP, deSouza NM. Diffusion-weighted MRI for imaging cell death after cytotoxic or apoptosis-inducing therapy. Br J Cancer. 2015;112(9):1471\u20139.","journal-title":"Br J Cancer"},{"issue":"3","key":"3937_CR32","first-page":"390","volume":"48","author":"L Brepoels","year":"2007","unstructured":"Brepoels L, Stroobants S, Vandenberghe P, Spaepen K, Dupont P, Nuyts J, et al. Effect of corticosteroids on 18F-FDG uptake in tumor lesions after chemotherapy. J Nucl Med. 2007;48(3):390\u20137.","journal-title":"J Nucl Med"},{"issue":"4","key":"3937_CR33","first-page":"603","volume":"47","author":"JM Engles","year":"2006","unstructured":"Engles JM, Quarless SA, Mambo E, Ishimori T, Cho SY, Wahl RL. Stunning and its effect on 3H-FDG uptake and key gene expression in breast cancer cells undergoing chemotherapy. J Nucl Med. 2006;47(4):603\u20138.","journal-title":"J Nucl Med"},{"issue":"12","key":"3937_CR34","doi-asserted-by":"publisher","first-page":"3051","DOI":"10.1093\/annonc\/mdx524","volume":"28","author":"JM Zaucha","year":"2017","unstructured":"Zaucha JM, Malkowski B, Chauvie S, Subocz E, Tajer J, Kulikowski W, et al. The predictive role of interim PET after the first chemotherapy cycle and sequential evaluation of response to ABVD in Hodgkin\u2019s lymphoma patients \u2013 the Polish Lymphoma Research Group (PLRG) Observational Study. Ann Oncol. 2017;28(12):3051\u20137.","journal-title":"Ann Oncol"},{"key":"3937_CR35","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1102\/1470-7330.2013.0006","volume":"13","author":"K Paepe De","year":"2013","unstructured":"De Paepe K, Bevernage C, De Keyzer F, Wolter P, Gheysens O, Janssens A, et al. Whole-body diffusion-weighted magnetic resonance imaging at 3 Tesla for early assessment of treatment response in non-Hodgkin lymphoma: a pilot study. Cancer Imaging. 2013;13:53\u201362.","journal-title":"Cancer Imaging"},{"issue":"1","key":"3937_CR36","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1148\/rg.301095088","volume":"30","author":"FM Paes","year":"2010","unstructured":"Paes FM, Kalkanis DG, Sideras PA, Serafini AN. FDG PET\/CT of extranodal involvement in non-Hodgkin lymphoma and Hodgkin disease. Radiographics. 2010;30(1):269\u201391.","journal-title":"Radiographics"},{"issue":"1","key":"3937_CR37","doi-asserted-by":"publisher","first-page":"25","DOI":"10.2967\/jnumed.109.067892","volume":"51","author":"M Weiler-Sagie","year":"2010","unstructured":"Weiler-Sagie M, Bushelev O, Epelbaum R, Dann EJ, Haim N, Avivi I, et al. (18)F-FDG avidity in lymphoma readdressed: a study of 766 patients. J Nucl Med. 2010;51(1):25\u201330.","journal-title":"J Nucl Med"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00259-018-3937-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-018-3937-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-018-3937-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,2,25]],"date-time":"2019-02-25T20:31:16Z","timestamp":1551126676000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00259-018-3937-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2,26]]},"references-count":37,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2018,6]]}},"alternative-id":["3937"],"URL":"https:\/\/doi.org\/10.1007\/s00259-018-3937-z","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"type":"print","value":"1619-7070"},{"type":"electronic","value":"1619-7089"}],"subject":[],"published":{"date-parts":[[2018,2,26]]},"assertion":[{"value":"13 October 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 January 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 February 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"None.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional research committee and with the principles of the1964 Declaration of Helsinki and its later amendments or comparable ethical standards.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}